John E Imhoff bought $126k of GTHP
director, owner at GUIDED THERAPEUTICS INC. 1,263,069 shares at an average of $0.10, traded Mar 18, 2025, filed May 23, 2025.
Score components
- +15RoleDirector
- +11Trade size$126k at market
- +3Relative to holdingsHoldings up 8%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +64.3%, 3m +87.9%, 6m +78.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001477932-25-004137, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 6, 2025 | JOther Preferred Series D Stock | -300 | - | - | 0 | May 23, 2025 |
| Mar 6, 2025 | JOther Common Stock | +900,000 | - | - | 9,662,756 | May 23, 2025 |
| Mar 6, 2025 | JOther Preferred Series C2 Stock | -2,401 | - | - | 0 | May 23, 2025 |
| Mar 6, 2025 | JOther Common Stock | +4,801,500 | $0.50 | $2.4M | 14,464,256 | May 23, 2025 |
| Mar 7, 2025 | POpen-market purchase Preferred Series C Stock | +286 | - | - | 286 | May 23, 2025 |
| Mar 11, 2025 | JOther Preferred Series C Stock | -286 | - | - | 0 | May 23, 2025 |
| Mar 11, 2025 | JOther Common Stock | +2,258,690 | $0.13 | $286k | 16,722,946 | May 23, 2025 |
| Mar 13, 2025 | POpen-market purchase Preferred Series E Stock | +150 | - | - | 400 | May 23, 2025 |
| Mar 18, 2025 | POpen-market purchase Common Stock | +1,000,000 | $0.10 | $100k | 17,722,946 | May 23, 2025 |
| Mar 18, 2025 | POpen-market purchase Common Stock | +263,069 | $0.10 | $26k | 17,986,015 | May 23, 2025 |
| Apr 10, 2025 | JOther Common Stock | +6,365 | - | - | 17,992,380 | May 23, 2025 |
| Mar 18, 2025 | POpen-market purchase Warrantsderivative | +1,000,000 | - | - | 1,000,000 | May 23, 2025 |
| Mar 18, 2025 | POpen-market purchase Warrantsderivative | +263,069 | - | - | 1,263,069 | May 23, 2025 |
Related signals
Other insiders at GUIDED THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | GUIDED THERAPEUTICS INC | Michael C James director | $5,000 27,778 shares | +5% | |
| 23Weak | GUIDED THERAPEUTICS INC | John E Imhoff director, owner | $30k 166,667 shares | +1% | |
| 37Weak | GUIDED THERAPEUTICS INC | John E Imhoff director, owner | $126k 1,263,069 shares | +8% | |
| 39Weak | GUIDED THERAPEUTICS INC | Michael C James director | $41k 412,945 shares | +366% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.